Estriol, a naturally occurring estrogen used in hormone therapy, was first identified and studied in the mid-20th century and later developed for clinical use in the management of menopausal symptoms, urinary tract health, and certain estrogen-deficient conditions. Its history is marked by its relatively mild estrogenic effects compared with estradiol and estrone, making it a preferred option in some hormone replacement therapies. Estriol is used in various formulations, including vaginal creams, suppositories, and oral preparations, and is often included in combination therapies for menopause management. Its development involved extensive clinical studies to determine optimal dosing and safety, with particular attention to minimizing systemic estrogen exposure while providing local therapeutic benefits.
BRAND NAMES
Ovestin – commonly used in Europe for vaginal or systemic hormone therapy.
Estriol – generic preparations in tablets, creams, or suppositories.
Gynest – vaginal cream formulation for menopausal symptoms.
MECHANISM OF ACTION
Estriol is a naturally occurring estrogen that exerts its effects by binding to estrogen receptors (ERα and ERβ) in target tissues, although it has a weaker affinity than estradiol or estrone. Once bound, the estriol-receptor complex dimerizes and interacts with estrogen response elements (EREs) in DNA, modulating gene transcription.
PHARMACOKINETICS
Absorption
Estriol can be absorbed via oral, vaginal, or rectal routes, with the rate and extent of absorption depending on the formulation. Oral estriol undergoes rapid absorption from the gastrointestinal tract, but a significant portion is subject to first-pass metabolism in the liver, which reduces systemic bioavailability.
Distribution
The volume of distribution of estriol reflects its distribution throughout the body after absorption. Estriol is moderately distributed, with an apparent Vd of approximately 2–4 L/kg, indicating it distributes beyond the plasma into tissues, particularly estrogen-sensitive organs such as the uterus, vagina, breasts, and liver.
Metabolism
Estriol undergoes extensive hepatic metabolism after absorption. It is primarily metabolized through conjugation reactions, forming estriol glucuronides and estriol sulfates, which are more water-soluble and can be readily excreted in urine and bile.
Elimination
Estriol is eliminated primarily through the urine as conjugated metabolites, including estriol glucuronides and sulfates, with only a minor portion excreted in bile. The elimination half-life of estriol is relatively short, typically around 2–5 hours, which contributes to its weaker and more transient estrogenic effects compared with estradiol.
PHARMACODYNAMICS
Estriol is a naturally occurring estrogen with weaker estrogenic activity compared with estradiol and estrone. It exerts its effects by binding to estrogen receptors ERα and ERβ in target tissues, where the estriol-receptor complex modulates gene transcription via estrogen response elements.
ADMINISTRATION
Estriol can be administered via oral, vaginal, or rectal routes, depending on the therapeutic goal. Oral tablets are used for systemic estrogen replacement, though they undergo significant first-pass metabolism in the liver.
DOSAGE AND STRENGTH
Estriol is available in multiple dosage forms and strengths depending on the route of administration and clinical purpose. Oral tablets typically contain 0.5 mg, 1 mg, or 2 mg of estriol, administered once or twice daily for systemic estrogen replacement. Vaginal creams usually provide 0.01% to 0.1% estriol, with doses ranging from 0.5 mg to 2 mg per application depending on the severity of symptoms.
DRUG INTERACTIONS
Estriol may interact with medications that affect liver enzyme activity, particularly cytochrome P450 (CYP) enzymes, altering its metabolism and effectiveness. Drugs that induce CYP3A4, such as rifampin, phenytoin, carbamazepine, or St. John’s Wort, can increase estriol metabolism, reducing its therapeutic effect.
FOOD INTERACTIONS
Estriol has minimal direct food interactions, and its absorption is generally not significantly affected by meals. Oral tablets can be taken with or without food without major changes in efficacy.
CONTRAINDICATIONS
Estriol is contraindicated in individuals with conditions that could be exacerbated by estrogen therapy. Absolute contraindications include a history of venous or arterial thromboembolism, stroke, myocardial infarction, or known hypersensitivity to estriol or any component of the formulation.
SIDE EFFECTS
Vaginal irritation or discharge
Breast tenderness or mild enlargement
Headaches or mild migraines
Nausea or gastrointestinal discomfort
Mild fluid retention or bloating
Mood changes.
Over Dosage
Overdosage of estriol, though uncommon, can occur with doses significantly exceeding therapeutic levels. Symptoms of acute overdose may include nausea, vomiting, abdominal pain, headaches, dizziness, fluid retention.
TOXICITY
Toxicity from estriol generally occurs only with prolonged high doses or inappropriate administration. Acute toxicity may present as nausea, vomiting, dizziness, headaches, fluid retention, and abnormal uterine bleeding. Chronic or excessive exposure can lead to more serious effects, including thromboembolic events, liver dysfunction, hypertension, and excessive proliferation of estrogen-sensitive tissues such as the endometrium and breasts.
